Program-at-a-Glance

1st Pan American Parkinson’s Disease and Movement Disorders Congress

FEBRUARY 24–26, 2017 MIAMI, FLORIDA, USA

www.pascongress2017.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Friday, February 24</th>
<th>Saturday, February 25</th>
<th>Sunday, February 26</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td></td>
<td>Plenary Session 8:00 - 10:00</td>
<td>Plenary Session 8:00 - 9:30</td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Plenary Session 9:30 - 11:00</td>
<td></td>
<td>Break 19:30 - 10:00</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Break 11:00 - 11:30</td>
<td></td>
<td>Plenary Session 10:00 - 12:00</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Plenary Session 11:30 - 13:30</td>
<td></td>
<td>Break 12:00 - 12:15</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>Break 13:30 - 14:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Break 16:30 - 17:00</td>
<td></td>
<td>Break 16:30 - 17:00</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td>Parallel Sessions 14:30 - 16:30</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Parallel Sessions 17:00 - 19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td>Skills Workshops 17:00 - 18:30</td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>Break 18:30 - 19:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>Opening Ceremony 19:00 - 21:00</td>
<td>Video Tournament 19:00 - 21:00</td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Dear Colleagues,

The International Parkinson and Movement Disorder Society (MDS) is pleased to introduce the 1st Pan American Parkinson’s Disease and Movement Disorders Congress. The meeting will be held on February 24-26, 2017 in Miami, Florida, USA.

As a result of the rapid growth of the MDS Pan American Section (MDS-PAS), there is the need for a forum to discuss relevant issues in our field that are specific to the Pan American Section. The 1st PAS Congress will incorporate practical workshops and ensure geographic and gender diversity in speaker selection and incorporate lecture topics that are cutting edge for both clinicians and basic scientists. This will also be a tremendous opportunity for MDS-PAS members to network with colleagues from different parts of Pan America.

Please visit www.pascongress2017.org to learn more about this inaugural event.

Warmest regards,

Cynthia Comella
Chair, PAS Congress Scientific Program Committee

Francisco Cardoso
Chair, MDS Pan American Section
## Friday, February 24, 2017

### 1101  Themed Plenary Session

**Parkinson’s Disease Across the Americas**

- **9:30 – 11:00**
  - **Chairs:** Oscar Gershanik
    Buenos Aires, Argentina
  - **9:30** How Levodopa Therapy for Parkinson’s Disease Came to be Developed in the Americas
    Stanley Fahn
    New York, NY, USA
  - **10:00** Parkinson’s Disease Genetics Across the Americas
    Jeffery Vance
    Miami, FL, USA
  - **10:30** Therapeutics: Accessibility, Cultural Differences and Habits Across the Americas
    Oscar Gershanik
    Buenos Aires, Argentina

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Describe the emergence of levodopa as a treatment for Parkinson’s disease: the American experience
2. Discuss the polymorphisms and risk alleles of the different populations in the Americas
3. Recognize how cultural differences, ingrained habits and access to different treatment options determine therapeutic decisions across the Americas

### 1102  Plenary Session, cont.

**The Spread of Synuclein in Parkinson’s Disease**

- **12:50**
  - **Jeffrey Kordower**
    Chicago, IL, USA

**Recommended Audience:** Basic scientists, Clinical academicians, Health Professionals (non-physician), Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Review the latest scientific findings regarding the presence of synuclein in the central and peripheral nervous system in Parkinson’s disease
2. Discuss recent data on the potential role of a tissue and fluid biomarkers
3. Discuss theories and evidence regarding the spread of synuclein in the pathogenesis of Parkinson’s disease

### 1103  Plenary Session

**Update on Parkinson’s Disease Therapeutics**

- **14:30 – 16:30**
  - **Chairs:** Federico Micheli
    Buenos Aires, Argentina
  - **14:30** Levodopa: Old Drug, New Approaches
    Robert Hauser
    Tampa, FL, USA
  - **15:10** Next Generation Deep Brain Stimulation
    Jill Ostrem
    Greenbrae, CA, USA
  - **15:50** Non-Motor Therapies: Present and Future
    Federico Micheli
    Buenos Aires, Argentina

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize how new delivery strategies are expanding the application of levodopa
2. Describe how newer techniques and technologies may impact use of DBS
3. Recognize current and emerging therapies for non-motor symptoms of Parkinson’s disease

### 1204  Parallel Session

**Dopaminergic and Cholinergic Imaging in Parkinson’s Disease**

- **17:00 – 19:00**
  - **Chairs:** A. Jon Stoessl
    Vancouver, BC, Canada
    Antonio Strafella
    Toronto, ON, Canada
  - **17:00** Presynaptic Dopaminergic Imaging and its Role in Parkinson’s Disease
    A. Jon Stoessl
    Vancouver, BC, Canada
  - **17:40** Imaging in Behavioral and Cognitive Complications in Parkinson’s Disease
    Antonio Strafella
    Toronto, ON, Canada
  - **18:20** Insights From Cholinergic Imaging in Parkinson’s Disease
    Nicolaas Bohnen
    Saline, MI, USA

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss the clinical and research utility of different presynaptic dopaminergic PET tracers in Parkinson’s disease
2. Recognize how dopaminergic imaging contributes to the understanding of cognitive and behavioral complications of Parkinson’s disease
3. Describe the insights provided by cholinergic imaging on the pathophysiology of non-dopaminergic features of Parkinson’s disease
Friday, February 24, 2017

**1205 Parallel Session**

**Surgical Procedures in Movement Disorders**
17:00 – 19:00

Chairs: Corneliu Luca
Miami, FL, USA
Jill Ostrem
Greenbrae, CA, USA

17:00 Lesions Versus Deep Brain Stimulation
Corneliu Luca
Miami, FL, USA

17:40 Latin America Experiences with Subthalamotomy
Jose Obeso
Madrid, Spain

18:20 Focused Ultrasound
William Jeffrey Elias
Charlottesville, VA, USA

**1206 Themed Parallel Session**

**Drug- Or Toxin-Induced Movement Disorders in America**
17:00 – 19:00

Chairs: Pedro Chana-Cuevas
Santiago, Chile
Caroline Tanner
San Francisco, CA, USA

17:00 Metal Exposure and Movement Disorders
Marcelo Miranda
Santiago, Chile

17:40 Toxin-Induced Movement Disorders
Caroline Tanner
San Francisco, CA, USA

18:20 Drug-Induced Movement Disorders
Pedro Chana-Cuevas
Santiago, Chile

Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Identify the factors that contribute to patient candidacy for various surgical treatments of Parkinson’s disease
2. Recognize the regional variability of surgical procedures performed for Parkinson’s disease and the long-term management of such patients
3. Recognize the utility of focused ultrasound in the treatment of movement disorders

Recommended Audience: Basic Scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the role of metal exposure (manganese, iron) in movement disorders
2. Recognize the pathogenic role of toxin (MPTP, Rotenone and Paraquat) in movement disorders
3. Describe the movement disorders associated with the use of drugs, from psychotropics to non psychotropics and identify clues leading to the suspicion of drug-induced movement disorders
### Saturday, February 25, 2017

<table>
<thead>
<tr>
<th>2101</th>
<th><strong>Themed Plenary Session</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyperkinetic Movement Disorders in Ethnic Populations in the Americas</strong></td>
<td><strong>Huntington's Disease Update</strong></td>
</tr>
<tr>
<td>8:00 – 10:00</td>
<td>10:30 – 12:00</td>
</tr>
<tr>
<td><strong>Chairs:</strong></td>
<td><strong>Chairs:</strong></td>
</tr>
<tr>
<td>Francisco Cardoso</td>
<td>Emilia Gatto</td>
</tr>
<tr>
<td>Belo Horizonte, Brazil</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>Rachel Saunders-Pullman</td>
<td>Blair Leavitt</td>
</tr>
<tr>
<td>New York, NY, USA</td>
<td>Vancouver, BC, Canada</td>
</tr>
</tbody>
</table>

### Plenary Session

**Huntington's Disease Update**

#### 10:30 – 12:00

- **Chairs:** Emilia Gatto, Buenos Aires, Argentina
- **Blair Leavitt, Vancouver, BC, Canada**

### 2102

**Hyperkinetic Movement Disorders in the Amish-Mennonite Population**

8:00

**Rachel Saunders-Pullman**

New York, NY, USA

**Genetic Dystonia in Brazil**

8:40

**Sarah Camargos**

São Paulo, Brazil

**Huntington's Disease-Like 2 and Other Huntington's Disease-Like Diseases in the Americas**

9:20

**Ruth Walker**

Bronx, NY, USA

**History of Huntington's Disease in the Americas**

10:30

**Roberto Weiser**

Caracas, Venezuela

**Phenotype-Genotype**

11:00

**Emilia Gatto**

Buenos Aires, Argentina

**Experimental Therapies in Huntington's Disease**

11:30

**Blair Leavitt**

Vancouver, BC, Canada

### Recommended Audience:

Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the hyperkinetic movement disorders found in the Amish-Mennonite population
2. Recognize the heterogeneity of genetic dystonias in Brazil
3. Discuss the epidemiology, genetics, and clinical features of HD like diseases in the Americas

---

**2203**

**Parallel Session, cont.**

### Genetics of Parkinson's Disease

**14:30 – 16:30**

- **Karen Marder**
  - Bronx, NY, USA
- **Andrew Singleton**
  - Bethesda, MD, USA

#### 16:30

**Genetics of Sporadic Parkinson's Disease**

Andrew Singleton

Bethesda, MD, USA

**Spectrum of LRRK2-and GBA-Associated Parkinson's Disease**

Karen Marder

Bronx, NY, USA

### Current Treatments and Future Directions

**Theresa Zesiewicz**

Oldsmar, FL, USA

#### 15:10

**Clinical Features and Work-Up**

Anelyssa D’Abreu

Campinas, Brazil

**Molecular Pathogenesis**

Stefan Pulst

Los Angeles, CA, USA

**Current Treatments and Future Directions**

Theresa Zesiewicz

Oldsmar, FL, USA

### Recommended Audience:

Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the role of polyglutamine expansion and other molecular issues on the pathophysiology of spinocerebellar ataxias
2. Recognize the main clinical features of the most prevalent spinocerebellar ataxias and improve the diagnostic approach
3. Provide management to subjects with spinocerebellar ataxia, including genetic counseling, rehabilitation, as well as current and future pharmacologic interventions
### Saturday, February 25, 2017

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Time</th>
<th>Chairs</th>
<th>Speakers</th>
<th>Location</th>
<th>Audience</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2205</td>
<td><strong>Parallel Session</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| | Parkinson’s Disease Across the PAS: Cross-Cultural Influences on its Neuropsychiatric Issues | 14:30 – 16:30 | Oscar Bernal-Pacheco, Chía, Colombia | Bonnie Levin, Miami, FL, USA | | | Chairs: Oscar Bernal-Pacheco, Chía, Colombia | Bonnie Levin, Miami, FL, USA
| | 14:30 | Neuropsychiatric Features of Parkinson’s Disease: Similarities and Differences Across the Americas | Oscar Bernal-Pacheco, Chía, Colombia | | | | Jennifer Goldman, Chicago, IL, USA
| | 15:10 | Cultural Influences on Perceptions and Treatments of Neuropsychiatric Features in Parkinson’s Disease | Jennifer Goldman, Chicago, IL, USA | | | | Bonnie Levin, Miami, FL, USA
| | 15:50 | Neuropsychological Evaluations in Parkinson’s Disease in the Context of Culture and Language | Bonnie Levin, Miami, FL, USA | | | | Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees
| | | At the conclusion of this session, participants should be better able to: | | | | | 1. Describe the epidemiology and clinical features of neuropsychiatric problems affecting cognition, behavior, and mood in Parkinson’s disease across the Pan Americas
2. Discuss how cultural differences influence our perceptions, recognition, and management of neuropsychiatric features in Parkinson’s disease
3. Discuss the effects of cultural and language on neuropsychological testing, normative data, particularly in the evaluation of neuropsychiatric features of Parkinson’s disease |

| 2306 | **Skills Workshop** | | | | | | |
| | Challenges to Publish Movement Disorders Research for Non-English Speakers | 17:00 – 18:30 | Christopher Goetz, Chicago, IL, USA | Marcelo Merello, Buenos Aires, Argentina | | | Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees
| | At the conclusion of this session, participants should be better able to: | | | | | | 1. Recognize that publication of research starts before writing a paper
2. Identify different ways of publishing their research
3. Discuss the most common style mistakes made by non-English speakers when writing a paper |

| 2307 | **Skills Workshop** | | | | | | |
| | MDS-UPDRS and UDysRS | 17:00 – 18:30 | Mayela Rodríguez Violante, Mexico City, Mexico | Glenn Stebbins, Chicago, IL, USA | | | Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees
| | At the conclusion of this session, participants should be better able to: | | | | | | 1. Describe the conceptual constructs of the MDS-UPDRS and UDysRS
2. Engage patients and caregivers in their role in the MDS-UPDRS and UDysRS
3. Complete sample ratings on items in the MDS-UPDRS and UDysRS |

| 2308 | **Skills Workshop** | | | | | | |
| | Chemodenervation in Movement Disorders | 17:00 – 18:30 | Robert Chen, Toronto, ON, Canada | Joseph Jankovic, Houston, TX, USA | | | Chairs: Robert Chen, Toronto, ON, Canada | Joseph Jankovic, Houston, TX, USA
| | 17:00 | Clinical and Pharmacological Aspects of Botulinum Toxins | Joseph Jankovic, Houston, TX, USA | | | | Cynthia Comella, Chicago, IL, USA
| | 18:00 | Applications in Parkinsonism | Robert Chen, Toronto, ON, Canada | | | | Recommended Audience: Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees
| | At the conclusion of this session, participants should be better able to: | | | | | | 1. Discuss the mechanisms of action and clinical pharmacological effects of the different formulations of Botulinum toxins
2. Describe the use of Botulinum toxin for the focal dystonias
3. Describe the use of Botulinum toxin in the treatment of the motor and non-motor manifestations of Parkinson’s disease |
### 3101 Plenary Session

**Hot Topics in Movement Disorders**  
8:00 – 9:30

**Chairs:**  
- Jorge Juncos  
  Atlanta, GA, USA  
- Irene Litvan  
  La Jolla, CA, USA

#### 8:00
**Deep Brain Stimulation for Tourette's Syndrome**  
Michael Okun  
Gainesville, FL, USA

#### 8:30
**Emerging Treatments for Tauopathies**  
Irene Litvan  
La Jolla, CA, USA

#### 9:00
**Stem Cell Tourism**  
Carlos Singer  
Fort Lauderdale, FL, USA

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Discuss current options for surgical intervention in Tourette's syndrome
2. Recognize recent advances in the treatment of Tauopathies
3. Discuss the risks of uncontrolled advertising of unsubstantiated stem cell treatments for neurodegenerative diseases

### 3102 Plenary Session

**Controversies**  
10:00 – 12:00

**Chairs:**  
- Cynthia Comella  
  Chicago, IL, USA  
- Marcelo Merello  
  Buenos Aires, Argentina

#### 10:00
**Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (YES)**  
Matthew Stern  
Philadelphia, PA, USA

#### 10:20
**Can We Diagnose Parkinson's Disease at an Early or Prodromal Stage? (NO)**  
Charles Adler  
Scottsdale, AZ, USA

#### 10:40
**Is There a Role for Immunotherapy for Synucleinopathies? (YES)**  
Elvira Valera  
La Jolla, CA, USA

#### 11:00
**Is There a Role for Immunotherapy for Synucleinopathies? (NO)**  
Ole Bacscon  
Belmont, MA, USA

#### 11:20
**Is Genetics In, and Clinical Phenomenology Out? (YES)**  
Laurie Ozelius  
Charlestown, MA, USA

#### 11:40
**Is Genetics In, and Clinical Phenomenology Out? (NO)**  
Connie Marras  
Toronto, ON, Canada

**Recommended Audience:** Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Understand the difficulties of an early diagnosis in Parkinson's disease
2. Assess the promises and pitfalls of immunotherapy in Parkinson's disease
3. Discuss the value of clinical phenomenology vs. whole exome sequencing

### 3203 Themed Parallel Session

**Inflammation, Infections and Immunity in Movement Disorders**  
14:30 – 16:30

**Chairs:**  
- Mayela Rodriguez Violante  
  Mexico City, Mexico  
- Helio Teive  
  Curitiba, Brazil

#### 14:30
**Inflammation and Movement Disorders**  
David Standaert  
Birmingham, AL, USA

#### 15:10
**Viral and Parasitic Infections**  
Carlos Cosentino  
Lima, Peru

#### 15:50
**Post Infectious and Autoimmune Movement Disorders**  
Francisco Cardoso  
Belo Horizonte, Brazil

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:
1. Recognize the role of inflammation in the pathophysiology of movement disorders
2. Identify the pathogenesis features of viral infection and parasitic causing movement disorders
3. Recognize the pathogenesis or post infectious and autoimmune movement disorders
Sunday, February 26, 2017

**3204 Parallel Session**

**Focus on the Patient/Family: Completing the Circle of Care in the Americas**

**14:30 – 16:30**

**Chairs**
Pedro Chana-Cuevas  
Santiago, Chile  
Ruth Hagstuen  
Minnetonka, MN, USA

**14:30** Focus on the Patient/Family: Completing the Circle of Care  
Ruth Hagstuen  
Minnetonka, MN, USA

**15:10** Home Management, Family and People with Parkinson’s Disease  
Daniela Alburquerque  
Santiago, Chile

**15:50** Palliative Care and Parkinson’s Disease  
Julie Carter  
Portland, OR, USA

**Recommended Audience:** Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Identify the impact of Parkinson’s disease on the care partners in the early, middle and advanced stages of Parkinson’s disease as well as options for support along the journey
2. Distinguish different alternatives in Parkinson’s disease care within the home, consider cultural and family perspective
3. Identify key palliative care with respect to Parkinson’s disease and how a palliative care approach can be used throughout the disease trajectory

---

**3205 Parallel Session**

**Rare Movement Disorders: What We Can Learn?**

**14:30 – 16:30**

**Chairs**
Emilia Gatto  
Buenos Aires, Argentina  
Anthony Lang  
Toronto, ON, Canada

**14:30** Approach to Rare Movement Disorders  
Anthony Lang  
Toronto, ON, Canada

**15:10** Neurodegeneration with Brain Iron Accumulation  
Susan Hayflick  
Portland, OR, USA

**15:50** Gaucher Disease and Niemann Pick Type C  
Emilia Gatto  
Buenos Aires, Argentina

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Non-physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize rare movement disorders and explain how these conditions contribute to the understanding of more common disorders
2. Explain clinical and pathologic features of degenerative disorders with brain iron accumulation
3. Discuss the clinical features, diagnosis and treatment of Gaucher disease and Niemann Pick Type C
Continuing Medical Education Information

Target Audience

The target participants of the 1st Pan American Congress are clinicians, researchers, medical residents, medical students and other non-physician health professionals who have an interest in the current research and issues in the field of movement disorders that are specific to the Pan American region.

Purpose

The purpose of the PAS Congress is consistent with the objectives of the MDS-PAS which include the following:

- Facilitate communication between clinicians and researchers in the region
- Disseminate updated knowledge about movement disorders
- Improve quality of life and independence of movement disorders patients and caregivers
- Promote research in Movement Disorders within the region
- Expose clinicians, researcher and healthcare professionals in the region to Movement Disorder initiatives and in so doing, encourage their membership in the MDS-PAS

Learning Objectives:

Through state-of-the-art lectures, hot topic reviews, controversy debates and Skills Workshops, participants will be better able to:

1. Describe the pathophysiology and neurobiology of Parkinson’s disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders
3. Discuss the pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other movement disorders

Intended Physician Competency Change (Attributes clinicians will gain/enhance due to participation in this activity):

- Provide patient-centered care
- Employ evidence-based practice
- Increase medical knowledge
- Practice-based learning and improvement
- Commitment to lifelong learning
- Cognitive expertise

Accreditation Statement:

The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The International Parkinson and Movement Disorder Society designates this educational activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Important Dates

September 1, 2016
Abstract Submission Deadline

January 24, 2017
Final Pre-Registration Deadline

February 24-26, 2017
1st Pan American Parkinson’s Disease
and Movement Disorders Congress

Scan to learn more on our website!